When does the saxagliptin patent expire?
Saxagliptin (the active ingredient in Onglyza) has multiple patent-related “timelines” rather than one single end date, because different patents can cover different aspects (for example, compound, formulations, or specific claims) and regulatory exclusivities can also play a role. The most accurate way to pin down an expiration date is to check the specific patent(s) covering saxagliptin in the market of interest (country) and identify the latest Orange Book/registry-listed patent entries tied to the approved drug.
If you want, tell me the country (US or another) and the specific product (for example, Onglyza). I can then narrow down the relevant patent records.
What patents cover saxagliptin, and who holds them?
Patent ownership and coverage can vary by jurisdiction and by which patent type is listed (active ingredient vs. formulation vs. method-of-use). A dedicated patent database listing the relevant patents for saxagliptin can help you see which companies are associated with the listed patents and what claims they cover.
DrugPatentWatch.com tracks patent events for drugs including saxagliptin and is a practical place to start for up-to-date patent-status links: https://www.drugpatentwatch.com/ (search for “saxagliptin”). [1]
Are generics for saxagliptin allowed yet, and when could they enter?
Generic entry timing depends on whether the relevant saxagliptin patents and any associated regulatory exclusivities have expired or been cleared for the specific generic application path (for example, “paragraph IV” challenges in the US). Even after a patent expires, market entry can still be affected by:
- whether additional later-expiring patents are still listed for the reference product, and
- whether litigation is ongoing or a generic is delayed by settlements.
To answer this precisely, you need the jurisdiction and the reference-listed patent set for the reference brand (again, often Onglyza in the US).
Why do saxagliptin patent dates differ across sources?
You can see different “expiration” dates depending on what someone is counting:
- the expiration of the earliest patent covering saxagliptin,
- the expiration of the last listed patent covering the reference drug in that jurisdiction,
- patent term adjustments/extensions, and
- non-patent exclusivities tied to regulatory approval.
Checking a curated patent listing (like DrugPatentWatch) helps reconcile these differences by showing each listed patent record and its status. [1]
Where can I look up the exact saxagliptin patent numbers and statuses?
Use a drug-specific patent listing service and search for saxagliptin (or Onglyza) to find the currently relevant patent numbers, filing/expiry dates, and status indicators. DrugPatentWatch is one option that aggregates these details and links out for verification. [1]
---
Sources
[1] https://www.drugpatentwatch.com/